Table 3.

Response rates and adverse events by starting lenvatinib dose.

Endpoint	KEYNOTE-775 len/pem, N= 411	Lenvatinib 10 mg starting dose, n = 10	Lenvatinib 14 mg starting dose, n = 10	Lenvatinib 20 mg starting dose, n = 23
Overall response rate	131 (31.9%)	3 (30%)	3 (30%)	7 (30%)
Clinical benefit rate	297 (72%)	7 (70%)	7 (70%)	16 (70%)
Best response
Partial response	104 (24.3%)	3 (30%)	3 (30%)	7 (33%)
Stable disease	193 (47%)	4 (40%)	4 (40%)	9 (43%)
Progression of disease	61 (14.8%)	3 (30%)	3 (30%)	5 (24%)
Missing	-	0	0	2
Time to response, months (range) Adverse events	2.1 (1.5–16.3)	2.5 (2.0–2.6)	2.8 (2.6–3.9)	2.8 (1.8–5.2)
Grade <3	-	1 (10%)	1 (10%)	4 (18%)
Grade ≥3	361 (88.9%)	9 (90%)	9 (90%)	18 (82%)

Adverse events graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.